NAACCR Item #3938: ALK Rearrangement
| Item # | Length | Source of Standard | Year Implemented | Version Implemented | Year Retired | Version Retired |
|---|---|---|---|---|---|---|
| 3,938 | 1 | NAACCR | 2021 | 21 |
NAACCR XML: Tumor.alkRearrangement
Description
Testing for ALK rearrangement is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify tumors which are sensitive to small-molecule ALK kinase inhibitors.
Rationale
ALK rearrangement is recommended by treatment guidelines for patients with advanced lung cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 01/01/2021+.
Codes
| 0 | Normal ALK negative Negative for rearrangement, no rearrangement identified, no mutations (somatic) identified, not present, not detected |
| 1 | Abnormal Rearrangement identified/detected: EML4-ALK, KIF5B-ALK, TFG-ALK, and/or KLC1-ALK |
| 2 | Rearrangement identified/detected: Other ALK Rearrangement not listed in code 1 |
| 4 | Rearrangement, NOS |
| 7 | Test ordered, results not in chart |
| 8 | Not applicable: Information not collected for this case If this information is required by your standard setter, use of code 8 may result in an edit error. |
| 9 | Not documented in medical record ALK Rearrangement not assessed or unknown if assessed |
| Blank | Diagnosis year is prior to 2021 |
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.